GlassScriptPhysician profile
Alexis Leyba
NPI 1942959424
$748.23
in general payments reported to CMS, 2019-2025
14 companies · $748 in 2025
The $748 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.24 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $193.78 | 2025 | Copiktra |
| Alexion Pharmaceuticals, INC. | $172.06 | 2025 | Soliris, Ultomiris |
| Incyte Corporation | $59.27 | 2025 | Monjuvi, Zynyz, Jakafi |
| Merck Sharp & Dohme LLC | $58.79 | 2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $50.08 | 2025 | |
| Syndax Pharmaceuticals, INC. | $33.13 | 2025 | |
| Amgen INC. | $32.48 | 2025 | |
| Coherus Oncology, INC. | $27.13 | 2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $25.71 | 2025 | Xpovio |
| Sumitomo Pharma America, INC. | $22.41 | 2025 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $21.24 | 2025 | Givlaari |
| Celgene Corporation | $20.90 | 2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2025 | Enhertu |
| Agios Pharmaceuticals, INC. | $14.67 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Leyba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.